Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02822105 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers
A Phase 1 study, sponsored by FluGen.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT02822105 is a Phase 1 study that has completed, run by FluGen. The registered enrollment target is 96 participants.
The verdict
NCT02822105, a Phase 1 study, has completed, sponsored by FluGen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose is of this study is to assess the safety and tolerability of three dose levels of H3N2 M2SR influenza vaccine versus placebo delivered intranasally to healthy adult subjects.
Interventions
- OTHER Placebo
- BIOLOGICAL the H3N2 M2SR monovalent influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2016-06 |
| Est. Completion | 2017-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02822105
The ClinicalTrials.gov registry entry for NCT02822105 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FluGen, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02822105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02822105 about?
NCT02822105 is a clinical study titled "Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers". The purpose is of this study is to assess the safety and tolerability of three dose levels of H3N2 M2SR influenza vaccine versus placebo delivered intranasally to healthy adult subjects.
What is the current status of trial NCT02822105?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2016-06. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02822105?
The interventions under investigation include: Placebo (OTHER), the H3N2 M2SR monovalent influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02822105?
This trial is sponsored by FluGen, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.